AGY Therapeutics said it is attempting to identify potential drugs that would treat cognitive symptoms of Alzheimer's, such as memory loss, disorientation, confusion, and reasoning and thinking problems, that may be linked to the AGY-110 enzyme.

"AGY-110 is a particularly exciting target because it could represent an entirely new therapeutic class for neuro-degenerative diseases, and is based on a pharmaceutically-valuable class of intracellular enzymes," said Dr. Karoly Nikolich, Chief Executive Officer of AGY Therapeutics.

"The effects of current cognition enhancement treatments have been modest to date at best, with many patients showing no improvement, creating a critical unmet medical need for novel treatments to improve patients' cognitive function and quality of life," said Roman Urfer, Ph.D., AGY's Vice President of Drug Discovery and Development.

"Our approach may be effective for patients who are not responsive to existing treatments or as a complementary therapy for those who do respond to existing treatments," Urfer said.

Other Sources: AGY Therapeutics, Inc.